BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Lung cancer AND ECT2L, 345930, C6orf91, Q008S8, LFDH, dJ509I19_3, dJ509I19_2, ENSG00000203734 AND Staging
4542 results:

  • 1. Development and validation of a nomogram to predict leptomeningeal metastases in lung adenocarcinoma: Cervical lymph node metastasis is an important association factor.
    Hua X; Feng W; Ye M; Lai M; Yu X; Sun M; Li J; Ai R; He Y; Cai L; Shi C; Liu X
    Cancer Med; 2024 May; 13(9):e7206. PubMed ID: 38686619
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. HBB as a Novel Biomarker for the Diagnosis and Monitoring of lung cancer Regulates Cell Proliferation via ERK1/2 Pathway.
    Xu X; Cai H; Peng J; Liu H; Chu F
    Technol Cancer Res Treat; 2024; 23():15330338241249032. PubMed ID: 38679728
    [No Abstract]    [Full Text] [Related]  

  • 3. A practical nomogram for predicting early death in elderly small cell lung cancer patients: A SEER-based study.
    Chen R; Liu Y; Tou F; Xie J
    Medicine (Baltimore); 2024 Apr; 103(17):e37759. PubMed ID: 38669410
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. [Construction and Validation of Prediction Models of Risk Factors for Early Death in Patients With Metastatic Melanoma].
    Li S; Li J; Yang Q; Yin C; Liu B
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2024 Mar; 55(2):367-374. PubMed ID: 38645854
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Clinical values of different specimen preparation methods for the diagnosis of lung cancer by EBUS-TBNA.
    Wang H; Wang J; Liu Y; Wang Y; Zhou Y; Yu D; You H; Ren T; Tang Y; Wang M
    Diagn Pathol; 2024 Apr; 19(1):61. PubMed ID: 38641621
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. The characteristics and prognosis of different disease patterns of multiple primary lung cancers categorized according to the 8th edition lung cancer staging system.
    Wang Y; Fang L; Hu X; Wu H; Zhou L; Xue Q; Gao S; He J
    J Cardiothorac Surg; 2024 Apr; 19(1):200. PubMed ID: 38600565
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Alectinib in Resected
    Wu YL; Dziadziuszko R; Ahn JS; Barlesi F; Nishio M; Lee DH; Lee JS; Zhong W; Horinouchi H; Mao W; Hochmair M; de Marinis F; Migliorino MR; Bondarenko I; Lu S; Wang Q; Ochi Lohmann T; Xu T; Cardona A; Ruf T; Noe J; Solomon BJ;
    N Engl J Med; 2024 Apr; 390(14):1265-1276. PubMed ID: 38598794
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. High risk of lung cancer in surfactant-related gene variant carriers.
    Brudon A; Legendre M; Mageau A; Bermudez J; Bonniaud P; Bouvry D; Cadranel J; Cazes A; Crestani B; Dégot T; Delestrain C; Diesler R; Epaud R; Philippot Q; Théou-Anton N; Kannengiesser C; Ba I; Debray MP; Fanen P; Manali E; Papiris S; Nathan N; Amselem S; Gondouin A; Guillaumot A; Andréjak C; Jouneau S; Beltramo G; Uzunhan Y; Galodé F; Westeel V; Mehdaoui A; Hirschi S; Leroy S; Marchand-Adam S; Nunes H; Picard C; Prévot G; Reynaud-Gaubert M; De Vuyst P; Wemeau L; Defossez G; Zalcman G; Cottin V; Borie R;
    Eur Respir J; 2024 May; 63(5):. PubMed ID: 38575158
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Analysis of related factors of CRA in lung cancer patients with different serum iron levels: A retrospective cohort study.
    Li QY; Yang WX; Liu H; Yao JL; Wang Q; Lin D; Shi J
    Cancer Med; 2024 Apr; 13(7):e7147. PubMed ID: 38562035
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. The radiological characteristics, tertiary lymphoid structures, and survival status associated with EGFR mutation in patients with subsolid nodules like stage I-II LUAD.
    Xie M; Gao J; Ma X; Song J; Wu C; Zhou Y; Jiang T; Liang Y; Yang C; Bao X; Zhang X; Yao J; Jing Y; Wu J; Wang J; Xue X
    BMC Cancer; 2024 Mar; 24(1):372. PubMed ID: 38528507
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Validation of an Updated Algorithm to Identify Patients With Incident Non-Small Cell lung cancer in Administrative Claims Databases.
    Patel SP; Wang R; Zhou SQ; Sheinson D; Johnson A; Lee JS
    JCO Clin Cancer Inform; 2024 Mar; 8():e2300165. PubMed ID: 38502111
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. The association of visceral pleural invasion with skip N2 metastasis on clinical stage IA NSCLC.
    Minamoto F; Araújo P; D'Ambrosio P; Dela Vega A; Lauricella L; Pêgo-Fernandes P; Terra R
    Clinics (Sao Paulo); 2024; 79():100334. PubMed ID: 38484584
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. lung cancer Diagnoses and Outcomes During the Syrian War, 2011-2018.
    Hanafi I; Abo Samra D; Alsaqqa R; Naeem A; Shebli B; Ajlyakin G
    JAMA Netw Open; 2024 Mar; 7(3):e242091. PubMed ID: 38477917
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Novel Functional Radiomics for Prediction of Cardiac Positron Emission Tomography Avidity in lung cancer Radiotherapy.
    Choi W; Jia Y; Kwak J; Werner-Wasik M; Dicker AP; Simone NL; Storozynsky E; Jain V; Vinogradskiy Y
    JCO Clin Cancer Inform; 2024 Mar; 8():e2300241. PubMed ID: 38452302
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Validation of the 9th edition of the TNM staging system for non-small cell lung cancer with lobectomy in stage IA-IIIA.
    Wang RR; Li MJ; Peng Q; Huang ZY; Wu LL; Xie D
    Eur J Cardiothorac Surg; 2024 Mar; 65(3):. PubMed ID: 38426334
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Exploration and machine learning model development for T2 NSCLC with bronchus infiltration and obstructive pneumonia/atelectasis.
    Jin X; Pan Y; Zhai C; Shen H; You L; Pan H
    Sci Rep; 2024 Feb; 14(1):4793. PubMed ID: 38413705
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Time between imaging and surgery is not a risk factor for upstaging of clinical stage IA non-small-cell lung cancer.
    Barcelos RR; Sugarbaker E; Kennedy KF; McAllister M; Kim S; Herrera-Zamora J; Leo R; Swanson S; Ugalde Figueroa P
    Eur J Cardiothorac Surg; 2024 Feb; 65(2):. PubMed ID: 38407382
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Factors affecting accuracy of clinical staging in resectable non-small cell lung cancer in a real-world study.
    Gwon HR; La Woo A; Yong SH; Park Y; Kim SY; Kim EY; Jung JY; Kang YA; Park MS; Park SY; Lee SH
    Thorac Cancer; 2024 Mar; 15(9):730-737. PubMed ID: 38380557
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Integration of on-treatment modified Glasgow prognostic score (mGPS) to improve imaging-based prediction of outcomes in patients with non-small cell lung cancer on immune checkpoint inhibition.
    Saal J; Bald T; Eckstein M; Ralser DJ; Brossart P; Ellinger J; Hölzel M; Klümper N
    Lung Cancer; 2024 Mar; 189():107505. PubMed ID: 38367405
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Relevance of tumor markers for prognosis and predicting therapy response in non-small cell lung cancer patients: A CEPAC-TDM biomarker substudy.
    Geiger K; Joerger M; Roessler M; Hettwer K; Ritter C; Simon K; Uhlig S; Holdenrieder S
    Tumour Biol; 2024; 46(s1):S191-S206. PubMed ID: 38363625
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 228.